<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588847</url>
  </required_header>
  <id_info>
    <org_study_id>02-AnIt-11</org_study_id>
    <nct_id>NCT01588847</nct_id>
  </id_info>
  <brief_title>Anesthesia and Cancer Recurrence im Malignant Melanoma</brief_title>
  <official_title>Long-term Outcome After Radical Lymph Node Dissection of Malignant Melanoma. Comparison Between Regional Versus General Anesthesia With Respect to Impact of Perioperative Immunoediting and Validation of New Potential Predictive Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies in animals and retrospective studies in humans show that regional anesthesia reduces
      metastatic cancer dissemination.

      The investigators hypothesize that in patients suffering from malignant melanoma who have to
      undergo radical inguinal lymph node dissection immune function will be less compromised and
      long term survival will be superior when spinal anesthesia is compared to general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Results of basic science indicate that regional anesthesia prevents perioperative
      immunosuppression and reduces postoperative metastatic cancer dissemination. If this would
      occur in humans, optimised anesthetic management might improve long-term outcome after cancer
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of the total amount of immune cells</measure>
    <time_frame>15 minutes before end of surgery</time_frame>
    <description>Change of the total amount of T-lymphocytes, B-lymphocytes, NK-cells, activity of NK-cells, changes in TGF-beta, activation status of thrombocytes from baseline until 15 minutes before end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the total amount of immune cells</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Change of the total amount of T-lymphocytes, B-lymphocytes, NK-cells, activity of NK-cells, changes in TGF-beta, activation status of thrombocytes from baseline until 15 minutes before end of surgeryfrom baseline until 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the total amount of immune cells</measure>
    <time_frame>Five days postoperatively</time_frame>
    <description>Change of the total amount of T-lymphocytes, B-lymphocytes, NK-cells, activity of NK-cells, changes in TGF-beta, activation status of thrombocytes from baseline until 15 minutes before end of surgeryfrom baseline until 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential predictive biomarkers</measure>
    <time_frame>15 minutes before end of surgery</time_frame>
    <description>Change of potential predictive biomarkers from baseline until 15 minutes before end of surgery postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential predictive biomarkers</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Change of potential predictive biomarkers from baseline until 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential predictive biomarkers</measure>
    <time_frame>Five days postoperatively</time_frame>
    <description>Change of potential predictive biomarkers from baseline until 5 days (plus or minus 1 day) postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Regional anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>General anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spinal anesthesia with Bupivacaine hyperbar 0.5 %</intervention_name>
    <description>Spinal anesthesia with Bupivacaine hyperbar 0.5 %</description>
    <arm_group_label>Regional anesthesia</arm_group_label>
    <other_name>Regional anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane</intervention_name>
    <description>General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane</description>
    <arm_group_label>General anesthesia</arm_group_label>
    <other_name>General anesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for inguinal lymph node dissection because of malignant melanoma of
             the lower limb

          -  Signed informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Female patients who are pregnant or nursing

          -  Multiple organ failure

          -  Contraindications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo K Van Aken, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster, Department of Anesthesia, Intensive Care and Pain Therapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerhard Brodner, Prof. Dr.</last_name>
    <phone>+49-251-3287-0</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Fachklinik Hornheide, Department of Anesthesiology, Intensive Care and Pain Therapy</name>
      <address>
        <city>MÃ¼nster</city>
        <zip>D-48157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Brodner, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>perioperative immunoediting</keyword>
  <keyword>potential predictive biomarkers</keyword>
  <keyword>lymph node dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

